Bank of New York Mellon Corp Lowers Stock Position in Solventum Corporation $SOLV

Bank of New York Mellon Corp cut its stake in shares of Solventum Corporation (NYSE:SOLV) by 6.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 810,933 shares of the company’s stock after selling 55,144 shares during the period. Bank of New York Mellon Corp’s holdings in Solventum were worth $64,258,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Hilltop National Bank grew its stake in shares of Solventum by 71.3% during the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after buying an additional 129 shares during the period. Measured Wealth Private Client Group LLC acquired a new position in shares of Solventum during the 3rd quarter valued at $25,000. JNBA Financial Advisors lifted its holdings in shares of Solventum by 205.4% during the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after acquiring an additional 228 shares in the last quarter. CYBER HORNET ETFs LLC acquired a new position in shares of Solventum during the 2nd quarter valued at $28,000. Finally, City State Bank lifted its holdings in shares of Solventum by 166.7% during the 4th quarter. City State Bank now owns 384 shares of the company’s stock valued at $30,000 after acquiring an additional 240 shares in the last quarter.

Solventum Price Performance

NYSE SOLV opened at $82.50 on Wednesday. Solventum Corporation has a 52 week low of $62.38 and a 52 week high of $88.20. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.96. The stock has a market cap of $14.29 billion, a price-to-earnings ratio of 10.11, a price-to-earnings-growth ratio of 1.22 and a beta of 0.69. The company has a 50-day moving average price of $71.58 and a two-hundred day moving average price of $75.25.

Solventum (NYSE:SOLV) last posted its earnings results on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.35 by $0.13. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The firm had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. During the same quarter in the prior year, the firm earned $1.34 EPS. Solventum’s quarterly revenue was down 3.0% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Analysts forecast that Solventum Corporation will post 6.58 EPS for the current year.

Wall Street Analyst Weigh In

SOLV has been the topic of a number of recent analyst reports. Wall Street Zen lowered shares of Solventum from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. UBS Group lowered shares of Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a report on Thursday, May 14th. Rothschild & Co Redburn initiated coverage on shares of Solventum in a report on Tuesday, March 24th. They issued a “sell” rating and a $60.00 price objective on the stock. Piper Sandler cut their price objective on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Finally, Stifel Nicolaus cut their target price on shares of Solventum from $105.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Eight investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Solventum has an average rating of “Moderate Buy” and an average target price of $84.25.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.